Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Author's Avatar
Nov 07, 2022

Personalis, Inc. (Nasdaq: PSNL) today announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society+for+Immunotherapy+of+Cancer+%28SITC%29+Annual+Meeting, November 8-12 in Boston, with three abstracts that highlight advanced R&D applications of next-generation sequencing (NGS) in immuno-oncology.